Winners and Losers in the Drug-Pricing War

Major pharmacy benefit managers and pharma stocks with innovative pipelines should see the most upside, while companies that rely heavily on price increases for growth will likely suffer, says Morningstar's Matt Coffina.

Copyright © 2019, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad
54°